Eli Lilly in big reshuffle: Sets up new units for neuroscience and immunology
The US-based pharmaceutical company has kicked off a big management reshuffle after a top-level decision ordered independent units for neuroscience and immunology, with the latter handling a potential launch of Alzheimer's drug donanemab.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN
Oncology and the larger Bio-Medicines division will be hit particularly hard now that Eli Lilly initiates a series of larger organizational changes.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.